BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 21437166)

  • 21. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
    Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
    Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.
    Paul E; Sutlu T; Deneberg S; Alici E; Björkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
    Oncol Rep; 2009 Jul; 22(1):137-42. PubMed ID: 19513515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
    Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
    Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
    Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
    Chim CS; Lie AK; Chan EY; Liu HS; Lau CW; Yip SF; Sim J; Wan TS; Ma ES; Liang R; Tse E; Kwong YL;
    J Hematol Oncol; 2012 Jun; 5():28. PubMed ID: 22682027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.
    Pisani F; Petrucci MT; Giannarelli D; Bongarzoni V; Montanaro M; De Stefano V; La Verde G; Gentilini F; Levi A; Za T; Moscetti A; Annino L; Petti MC;
    J Exp Clin Cancer Res; 2012 Mar; 31(1):17. PubMed ID: 22381082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine.
    Shimazu Y; Mizuno S; Fuchida SI; Suzuki K; Tsukada N; Hanagaishi A; Itagaki M; Kataoka K; Kako S; Sakaida E; Yoshioka S; Iida S; Doki N; Oyake T; Ichinohe T; Kanda Y; Astuta Y; Takamatsu H;
    Cancer Sci; 2021 Dec; 112(12):5034-5045. PubMed ID: 34644446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
    Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
    Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
    [No Abstract]   [Full Text] [Related]  

  • 37. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
    Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G; Merritt L; Ketcham J; Heerema N; Byrd JC; Devine SM; Efebera YA
    Leuk Lymphoma; 2013 Aug; 54(8):1658-64. PubMed ID: 23194056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
    Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.